News & Events

Published On: 12/15/2021

Target RWE Dermatology Study Data Shared at 3rd Annual RAD Conference

Latest real-world TARGET-DERM AD abstract posters accepted to virtual event

In December 2021, Target RWE participated in the annual Revolutionizing Atopic Dermatitis (RAD) conference and presented two posters from the company’s active longitudinal real-world study, TARGET-DERM AD.

The first poster (#632) entitled, Epidemiology and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM-AD cohort, was selected for oral presentation. It was presented by Lawrence Eichenfield, MD, Professor of Dermatology and Pediatrics at Rady Children’s Hospital in San Diego, CA. This real-world analysis of patients with AD found that difficult to treat areas were associated with significantly higher impact on health-related quality of life (HRQoL). In addition, patients with affected head, face, neck, or hands were more likely than those without to have severe disease than those who did not (28.5% vs. 16.3%, p=0.02). These TARGET-DERM AD results highlight the importance of detailed assessment of specific areas affected by AD for more personalized approaches to best address the needs of patients.

The second TARGET-DERM AD abstract poster (#644) was titled Disease burden in atopic dermatitis is associated with higher symptom severity and lower quality of life: TARGET-DERM AD real world study. This analysis aimed to highlight associations between clinician-reported validated Investigator Global Assessment for AD (vIGA-AD) and patient-reported burden of disease. The study found that greater disease severity is significantly associated with higher symptom severity and lower quality of life.

“The real-world data findings presented at this year’s RAD conference underline the importance of detailed documentation and generation of research in the field of atopic dermatitis,” said Target RWE Vice President of RWE and Strategic Partnerships, Julie Crawford, MD.

TARGET-DERM is a global observational study following adult and pediatric patients with immune-mediated inflammatory skin conditions from the U.S., Canada, and Europe. Learn more about Target RWE’s publications here.

About Target RWE

Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.

Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.

Contact:

Kayla Slake
Marketing Manager

kslake@targetrwe.com

984.234.0268 ext 205